Our news
- 18/07/2019: Pharegis implemented optimized procedures for state registration of pharmaceuticals in Eurasian Economic Union.
- 20/06/2019: Pharegis updated timelines and practical approaches for Russian and EEU GMP inspection applications and procedures.
- 03/04/2019: Renewed general monographs of Russian state pharmacopeia XIV ed. have been analyzed.
Global industry news
Contact us
Activities
Regulatory Events Russia
Russian Regulatory News
Pharegis LLC / ООО "Фареджис"
-
- Business address:
3-1 Begovaya str. ("NordStar Tower", 31st fl.), Moscow, Russia 125284
Legal & postal address:
11A-11 Cherkizovskaya B. str., Moscow, Russia 107392
D-U-N-S: 362071645
-
- + 7 985 908 58 18 9am-6pm GMT+3
-
- http://www.pharegis.com
Regulatory news
Drugs.com - New Drug Approvals
- FDA Approves Saphnelo (anifrolumab) for Moderate to Severe Systemic Lupus Erythematosus
- Uptravi (selexipag) Receives FDA Approval for Intravenous Use in Adult Patients with Pulmonary Arterial Hypertension (PAH)
- GSK Announces FDA Approval for Nucala (mepolizumab) for use in Adults with Chronic Rhinosinusitis with Nasal Polyps
- FDA Approves Expanded Botox (onabotulinumtoxinA) Label to Include Eight New Muscles to Treat Adults with Upper Limb Spasticity
- FDA Approves Semglee (insulin glargine-yfgn) as the First Interchangeable Biosimilar Insulin Product for Treatment of Diabetes
News and press releases
- ECDC and EMA update on COVID-19, , 04/08/2021
- Six-month countdown to go-live for the Clinical Trials Information System (CTIS), , 02/08/2021
- Increased manufacturing capacity and supply for Spikevax, CHMP, 30/07/2021
- COVID-19 vaccine Spikevax approved for children aged 12 to 17 in EU, CHMP, 23/07/2021
Drugs.com - Clinical Trials
- Complete Response Letter Received from FDA for Treosulfan TORONTO and CHICAGO and...
- FDA Expands Authorized Use of REGEN-COV (casirivimab and imdevimab) TARRYTOWN, N.Y., July...
- Lilly Releases Donanemab Data That Demonstrated Relationship Between Reduction of Amyloid Plaque and Slowing of Cognitive Decline INDIANAPOLIS, July 29,...
- FDA Broadens Existing Emergency Use of Lilly and Incyte's Baricitinib in Patients Hospitalized with COVID-19 Requiring Oxygen INDIANAPOLIS, July 29,...
PharmaTimes: PharmaTimes Website RSS
- BMS withdraws Istodax as a treatment for peripheral T-cell lymphoma
- MHRA approves Opdivo plus Yervoy for unresectable malignant pleural mesothelioma
- UK trial to assess Sativex for the treatment of ‘aggressive’ brain tumours
- Long COVID rare in children, KCL study finds
- CMA fines Advanz over ‘excessive and unfair’ pricing of thyroid drug